C Bredeson1, R B Rumble2, N P Varela3, J Kuruvilla4, C T Kouroukis5. 1. The Ottawa Hospital Research Institute, and Department of Medicine, University of Ottawa, Ottawa, ON. 2. American Society of Clinical Oncology, Alexandria, VA, U.S.A. (The opinions expressed in this article are those of the authors and do not necessarily represent the views of the American Society of Clinical Oncology.). 3. Cancer Care Ontario, Program in Evidence-Based Care, McMaster University, Hamilton, ON. 4. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON. 5. Division of Malignant Hematology, Juravinski Cancer Centre, McMaster University, Department of Oncology, Hamilton, ON.
Abstract
QUESTION: Is there a benefit associated with the use of extracorporeal photopheresis (ecp) compared with other treatment options for patients who have received allogeneic stem-cell transplantation (sct) and are experiencing graft-versus-host disease (gvhd), if response rate, survival, or improvement in symptoms are the outcomes of interest? PERSPECTIVES: After allogeneic sct, gvhd is a common complication historically categorized as either acute (agvhd: onset ≤100 days post-transplantation) or chronic (cgvhd: >100 days post-transplantation). Graft-versus-host disease occurs when the donor's immune cells recognize the host patient's tissues and organs as foreign and attack them, causing a multitude of problems, often in liver, gastrointestinal system, and skin. Photopheresis is one therapy that has emerged since the early 2000s for the management of steroid-refractory gvhd because of its steroid-sparing ability, low associated toxicity, and efficacy in some clinical settings. The present recommendation report summarizes the available data about photopheresis for the treatment of gvhd and provides recommendations on its use. METHODOLOGY: The medline (Ovid) database was systematically searched for January 1995 to August 2013, and the best available evidence was used to draft recommendations relevant to adult and pediatric patients in Ontario who have received allogeneic sct and are experiencing gvhd. Draft recommendations were first reviewed by clinical and methodology experts before undergoing internal review. Final approval of this practice guideline report was obtained from both the Stem Cell Transplant Steering Committee and the Report Approval Panel of the Program in Evidence-Based Care. RECOMMENDATIONS: These recommendations apply to adult and pediatric patients who have received an allogeneic sct and are experiencing gvhd: ecp is an acceptable therapy for the treatment of steroid-dependent or refractory agvhd in adult and pediatric patients.ecp is an effective therapy for the treatment of steroid-dependent or refractory cgvhd in adult and pediatric patients. QUALIFYING STATEMENT: In Ontario, ecp is currently a covered therapy for patients with steroid-refractory gvhd who meet certain eligibility criteria.
QUESTION: Is there a benefit associated with the use of extracorporeal photopheresis (ecp) compared with other treatment options for patients who have received allogeneic stem-cell transplantation (sct) and are experiencing graft-versus-host disease (gvhd), if response rate, survival, or improvement in symptoms are the outcomes of interest? PERSPECTIVES: After allogeneic sct, gvhd is a common complication historically categorized as either acute (agvhd: onset ≤100 days post-transplantation) or chronic (cgvhd: >100 days post-transplantation). Graft-versus-host disease occurs when the donor's immune cells recognize the host patient's tissues and organs as foreign and attack them, causing a multitude of problems, often in liver, gastrointestinal system, and skin. Photopheresis is one therapy that has emerged since the early 2000s for the management of steroid-refractory gvhd because of its steroid-sparing ability, low associated toxicity, and efficacy in some clinical settings. The present recommendation report summarizes the available data about photopheresis for the treatment of gvhd and provides recommendations on its use. METHODOLOGY: The medline (Ovid) database was systematically searched for January 1995 to August 2013, and the best available evidence was used to draft recommendations relevant to adult and pediatric patients in Ontario who have received allogeneic sct and are experiencing gvhd. Draft recommendations were first reviewed by clinical and methodology experts before undergoing internal review. Final approval of this practice guideline report was obtained from both the Stem Cell Transplant Steering Committee and the Report Approval Panel of the Program in Evidence-Based Care. RECOMMENDATIONS: These recommendations apply to adult and pediatric patients who have received an allogeneic sct and are experiencing gvhd: ecp is an acceptable therapy for the treatment of steroid-dependent or refractory agvhd in adult and pediatric patients.ecp is an effective therapy for the treatment of steroid-dependent or refractory cgvhd in adult and pediatric patients. QUALIFYING STATEMENT: In Ontario, ecp is currently a covered therapy for patients with steroid-refractory gvhd who meet certain eligibility criteria.
Entities:
Keywords:
Stem-cell transplantation; bone marrow; graft-versus-host disease; peripheral blood; photopheresis
Authors: Emil Bisaccia; Mark Palangio; Joselyn Gonzalez; Kenneth R Adler; Richard Scarborough; Stuart L Goldberg; Scott D Rowley Journal: J Clin Apher Date: 2006-10 Impact factor: 2.821
Authors: Paul J Martin; Yoshihiro Inamoto; Mary E D Flowers; Paul A Carpenter Journal: Biol Blood Marrow Transplant Date: 2012-04-14 Impact factor: 5.742
Authors: Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter Journal: Biol Blood Marrow Transplant Date: 2012-04-14 Impact factor: 5.742
Authors: L Salvaneschi; C Perotti; M Zecca; S Bernuzzi; G Viarengo; G Giorgiani; C Del Fante; P Bergamaschi; R Maccario; A Pession; F Locatelli Journal: Transfusion Date: 2001-10 Impact factor: 3.157
Authors: E Calore; A Calò; G Tridello; S Cesaro; M Pillon; S Varotto; M V Gazzola; R Destro; P Marson; L Trentin; M Carli; C Messina Journal: Bone Marrow Transplant Date: 2008-06-23 Impact factor: 5.483
Authors: G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff Journal: Bone Marrow Transplant Date: 2011-03-28 Impact factor: 5.483
Authors: Madan Jagasia; Christof Scheid; Gérard Socié; Francis Ayuketang Ayuk; Johanna Tischer; Michele L Donato; Árpád Bátai; Heidi Chen; Sheau-Chiann Chen; Thomas Chin; Henri Boodée; Ghaith Mitri; Hildegard T Greinix Journal: Blood Adv Date: 2019-07-23
Authors: Jennifer Seelisch; Lillian Sung; Michael J Kelly; Jennifer L Raybin; Melissa Beauchemin; Christopher C Dvorak; Katherine Patterson Kelly; Michael L Nieder; Robert B Noll; Jennifer Thackray; Nicole J Ullrich; Sandra Cabral; L Lee Dupuis; Paula D Robinson Journal: Pediatr Blood Cancer Date: 2018-09-26 Impact factor: 3.167